GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
01/07/26	NT$25.15	-1.76%	243,712
30/06/26	NT$25.60	+0.39%	224,376
29/06/26	NT$25.50	+3.66%	360,485
26/06/26	NT$24.60	-4.65%	269,047
25/06/26	NT$25.80	0.00%	240,793

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange Other stock markets 01/07/2026			5-day change	1st Jan Change
25.15 ^TWD	-1.76%		-2.52%	-2.33%

06-11	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	2.83B 88.79M 77.96M 71.76M 66.86M 126M 8.44B 129M 863M 334M 4.14B 333M 326M 14.42B	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	2.61B 81.9M 71.91M 66.19M 61.67M 116M 7.79B 119M 796M 308M 3.82B 307M 301M 13.3B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	80.91%	Yield 2024 *	-	Yield 2025	-

06-11	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
03-23	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
03-14	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-08	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
11-24	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
11-14	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
29/10/25	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
29/10/25	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
14/08/25	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
13/06/25	GlycoNex, Inc. Announces Publication of Preclinical Study on Gnx1021, A Novel Glycan-Targeted Adc for Gastric Cancer	CI
28/05/25	GlycoNex, Inc. Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules	CI

1 day	-1.76%
1 week	-2.52%
Current month	-1.76%
1 month	-3.82%
3 months	+7.94%
6 months	-2.33%
Current year	-2.33%

GlycoNex Incorporation Stock

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news : GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Course Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	24.6	26.4
1 month	24.6	30
Current year	22.1	30
1 year	20.55	30
3 years	15.6	32.9
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	01/01/2019
Dih Fen Wu DFI	Director of Finance/CFO	-	01/01/2010
Yao Hua Lue IRC	Investor Relations Contact	-	12/11/2012

Director	Title	Age	Since
Tong Hsuan Chang CHM	Chairman	-	01/02/2001
Kao Chung Tsai BRD	Director/Board Member	64	-
Ling-Chun Tsai BRD	Director/Board Member	-	25/05/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	-1.76%	-2.52%	+0.20%	-21.04%	88.79M
LONZA GROUP AG	-0.02%	+4.84%	+0.79%	+6.38%	48.62B
REVOLUTION MEDICINES, INC.	+0.12%	+10.45%	+408.29%	+600.97%	39.86B
IQVIA HOLDINGS INC.	+5.17%	+9.47%	+24.96%	-9.60%	33.91B
BEONE MEDICINES AG	+2.02%	+4.91%	+18.59%	+63.06%	32.32B
CELLTRION, INC.	+0.69%	+1.04%	+14.23%	+30.86%	24.73B
ASCENDIS PHARMA A/S	+0.40%	+12.51%	-	-	16.63B
MEDPACE HOLDINGS, INC.	+2.64%	+6.00%	+69.30%	+126.33%	15.52B
EUROFINS SCIENTIFIC SE	+0.23%	+0.50%	+13.12%	+17.82%	13.63B
ICON PUBLIC LIMITED COMPANY	+0.77%	+10.67%	+17.58%	-30.04%	13.41B
Average	+1.01%	+6.09%	+63.01%	+87.20%	23.87B
Weighted average by Cap.	+1.33%	+7.14%	+88.27%	+128.51%

	2024	2025
Net sales	14.7M 461K 405K 373K 347K 655K 43.85M 668K 4.48M 1.74M 21.53M 1.73M 1.69M 74.91M	37.86M 1.19M 1.04M 960K 895K 1.69M 113M 1.72M 11.55M 4.47M 55.44M 4.46M 4.36M 193M
Net income	-230M -7.21M -6.33M -5.82M -5.43M -10.24M -685M -10.44M -70.05M -27.14M -336M -27.06M -26.48M -1.17B	-235M -7.38M -6.48M -5.96M -5.56M -10.48M -702M -10.69M -71.74M -27.8M -344M -27.71M -27.11M -1.2B
Net Debt	-442M -13.87M -12.18M -11.21M -10.45M -19.7M -1.32B -20.1M -135M -52.24M -647M -52.08M -50.96M -2.25B	-220M -6.89M -6.05M -5.57M -5.19M -9.79M -655M -9.99M -67M -25.96M -322M -25.88M -25.32M -1.12B